Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. immunogrow

ImmunoGrow

Making life-saving cancer therapies more widely available by simplifying production processes, reducing costs and enhancing patient safety through its patent-protected biomimicking mesh material.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 ImmunoGrow project word cloud

Explore the words cloud of the ImmunoGrow project. It provides you a very rough idea of what is the project "ImmunoGrow" about.

conduct    core    plan    treatments    treatment    seed    helps    remission    shown    variability    anticipated    patient    solutions    trials    2030    mesh    release    500    body    market    skilled    ltd    83    engineered    save    unless    prohibitive    initial    life    patent    requirement    infrastructure    fund    gmt    significantly    consumables    manufacturers    immunogrow    cells    cheaper    achieves    patients    full    reduce    manufacture    cancer    changing    produces    mimics    cell    costly    immune    grey    car    dynabeads    expects    15    ing    untreatable    8x    capture    activation    citizens    2021    performance    closed    475    customers    publically    safer    natural    seeking    feasibility    business    600mn    independent    simplifying    therapies    input    priced    individualised    lab    genetically    lifesaving    gold    round    2019    addressable    tests    standard    cleanroom    yield    harness    sickest    structure    limitations    poor    labour    aggressive    encounter    cancers    limited    protected    expensive    technologies    reducing    operator    automated    prices    rates    healthcare    q3    struggling   

Project "ImmunoGrow" data sheet

The following table provides information about the project.

Coordinator		 Grey Matter Technologies Limited 

Organization address
address: MERTON BREE ENNISCORTHY
city: WEXFORD
postcode: Y21 Y5V0
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Ireland [IE]
 Project website http://www.immunogrow.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2019-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    Grey Matter Technologies Limited IE (WEXFORD) coordinator 50˙000.00

Map

 Project objective

Lifesaving cell-based CAR-T therapies have achieved remission rates of up to 83% for patients with the most aggressive and untreatable cancers. These therapies harness a patient’s own genetically engineered immune cells to target cancer cells. However, manufacturers are struggling to produce these individualised treatments at scale resulting in prohibitive prices as high as $475,000 per treatment. Unless solutions that address these limitations are provided, publically-funded EU healthcare systems & citizens will be priced out of these life-changing therapies.

The challenges they face include poor cell growth performance due to patient sample variability, limitations associated with equipment adopted from the research lab that require costly skilled labour, costly consumables and expensive cleanroom infrastructure.

Compared to the gold standard, Dynabeads, initial testing has shown that the ImmunoGrow technology produces an 8x higher cell yield which helps to save the sickest patients who have limited cells and significantly reduce the cost to manufacture these therapies by simplifying the process, reducing the requirement for skilled operator input and making this step both ‘closed’ and automated. ImmunoGrow achieves this through its patent-protected mesh structure that mimics the natural growth conditions cells encounter in the body.

Grey Matter Technologies (‘GMT’) Ltd. is seeking support to help fund trials with two identified customers as well to help it to conduct an independent set of tests on the product’s performance. Both these trials, as well as an associated business plan or feasibility study, will be core to the raising of a seed round of €500,000 in 2019 to further develop the technology with the release of a full-scale product anticipated for Q3 2021. GMT expects to capture 15% of the $600mn addressable T-Cell Activation market in 2030. In doing so, it will make these life changing treatments cheaper, safer and more widely available.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNOGROW" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUNOGROW" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More